Gene editing company Precision BioSciences (Nasdaq:DTIL) has announced that preclinical research involving in vivo gene editing targeting hepatitis B virus (HBV) has been published in Molecular Therapy. In the research, the company used an engineered ARCUS nuclease (ARCUS-POL) targeting the Hepatitis B virus (HBV) genome. In this preclinical study, ARCUS efficiently targeted and degraded HBV covalently…

Assembly Biosciences (NSDQ:ASMB) is halting the development of the hepatitis drug ABI-H2158 (2158) after observing elevated alanine aminotransferase (ALT) in participants in a Phase 2 trial. High ALT levels can indicate liver damage. “Patient safety is always our priority, which is why we have elected to discontinue the development of 2158,” said Dr. John McHutchison,…